J&J submits simeprevir application in Japan

Medivir AB (SSE:MVIR B) said partner Johnson & Johnson (NYSE:JNJ) submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for simeprevir ( TMC435) to treat HCV genot...